COMP <GO>
UTMD vs ABBV // REVENUE GROWTH (YOY)
Utah Medical Products Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: UTMD 3
— ABBV 7
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $66.80 (-2.96%) • MKT CAP: $212.7M
revenue-growth
-5.80%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.10% | 70.20% | -13.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.90% | 29.00% | -2.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 10.8x | 33.3x | -22.50 | UTMD | /valuation <GO> |
| Free Cash Flow Yield | 6.73% | 3.47% | +3.26 | UTMD | /fcf-yield <GO> |
| Operating Margin | 29.60% | 24.60% | +5.00 | UTMD | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -5.80% | 8.60% | -14.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.87% | 2.27% | -0.40 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.2 | 65.1 | -37.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $212.7M | $513.86B | -$513.65B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTMD REV | ABBV REV | UTMD GROSS % | ABBV GROSS % | UTMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.5M | $61.16B | 57.1% | 70.2% | $14.3M | $17.82B |
| FY 2024 | $40.9M | $56.33B | 59.0% | 70.0% | $14.6M | $17.83B |
| FY 2023 | $50.2M | $54.32B | — | — | $22.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTMD // BETA —
ABBV // BETA 1.15